
ReproNovo has dosed the first participant in its phase 2 NORDIC study evaluating RPN-002, an investigational therapy designed to improve …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

